PharmaResearch Balance Sheet Health
Financial Health criteria checks 6/6
PharmaResearch has a total shareholder equity of ₩509.1B and total debt of ₩32.0B, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are ₩601.5B and ₩92.4B respectively. PharmaResearch's EBIT is ₩105.3B making its interest coverage ratio -17. It has cash and short-term investments of ₩206.1B.
Key information
6.3%
Debt to equity ratio
₩31.99b
Debt
| Interest coverage ratio | -17x |
| Cash | ₩206.07b |
| Equity | ₩509.11b |
| Total liabilities | ₩92.37b |
| Total assets | ₩601.47b |
Recent financial health updates
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08
Recent updates
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today
May 21PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25Financial Position Analysis
Short Term Liabilities: A214450's short term assets (₩312.1B) exceed its short term liabilities (₩84.8B).
Long Term Liabilities: A214450's short term assets (₩312.1B) exceed its long term liabilities (₩7.5B).
Debt to Equity History and Analysis
Debt Level: A214450 has more cash than its total debt.
Reducing Debt: A214450's debt to equity ratio has reduced from 8.6% to 6.3% over the past 5 years.
Debt Coverage: A214450's debt is well covered by operating cash flow (326%).
Interest Coverage: A214450 earns more interest than it pays, so coverage of interest payments is not a concern.